Anti-IgE therapy (omalizumab) is indicated for severe persistent allergic asthma, which is uncontrolled despite appropriate therapy according to current GINA guidelines.Aim of this study
Aim of this study was to describe changes of selected parameters (FEV1, life quality and FeNO50) in all patients treated with omalizumab in the Czech Republic for more than 12 months in a real life clinical setting.Methods
Data of 127 patients treated 12 months by omalizumab in eight Czech centres were prospectively observed in Czech Anti-IgE Registry and analysed. Respiratory specialist and allergist together decided indication of anti-IgE therapy after extensive evaluation process in each patient.Results
Median IgE level was 223 IU/ml, all patients experienced during previous year at least two exacerbation treated by oral steroid burst. 69 patients were dependent on oral steroids, mean dose 5 mg prednisolone/day. After 12 months of omalizumab therapy FEV1 improved from 65% to 72% (p<0.001), asthma control test changed from 13 to 18 points score (p<0.001) and FeNO50 decreased from 48 to 32 ppb (p=0.001). Emergency visits, steroid bursts for asthma exacerbation and mean oral steroid dose were lower after the 12 months of therapy as well (all p<0.001). Observed side effects were mild (headache, weight gain) in 21.3% patients. Overall response to anti-IgE therapy measured by clinical evaluation of treatment benefit was 80.8%.Conclusion
Rigorous selection of candidates for anti-IgE therapy based on consensus of allergology and respiratory specialists leads to very good therapeutic response, we have observed significant improvement in lung functions.